News | April 01, 2022
Oragnon enters global licencing agreement with Dare Biosciences
An estimated 21 million American women experience BV
An estimated 21 million American women experience BV
It is an application to automate statistical analysis and reporting for clinical research.
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
The investment will accelerate the overall Sarclisa development program
Subscribe To Our Newsletter & Stay Updated
